X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/tarsier-pharma-receives-fda-agreement-under-special-protocol-assessment-spa-for-tarsier-04-phase-3-trial-of-trs01-ophthalmic-solution-for-the-treatment-of-non-infectious-uveitis-including-uveitic-glaucoma-302035761.html
https://www.prnewswire.com/news-releases/tarsier-pharma-announces-successful-type-c-meeting-with-fda-for-trs01-in-noninfectious-uveitis-301985947.html
https://www.prnewswire.com/news-releases/tarsier-pharma-announces-results-from-a-phase-3-clinical-trial-in-subjects-with-noninfectious-anterior-uveitis-including-subjects-with-uveitic-glaucoma-301907809.html
https://www.prnewswire.com/news-releases/tarsier-pharma-announces-publication-of-review-article-on-suppressing-inflammation-for-treating-retinal-blinding-ocular-diseases-highlighting-dazdotuftide-trs-as-a-promising-therapeutic-candidate-301848223.html
https://www.prnewswire.com/news-releases/tarsier-pharma-announces-international-non-proprietary-name-for-trs-301805284.html
https://www.prnewswire.com/news-releases/tarsier-pharma-announces-participation-in-the-hc-wainwright-2nd-annual-ophthalmology-virtual-conference-301601540.html
https://www.biospace.com/article/releases/first-patient-randomized-in-tarsier-pharma-s-trs4vision-phase-iii-clinical-trial-in-patients-with-active-non-infectious-anterior-uveitis-including-patients-with-uveitic-glaucoma/?s=71
https://www.prnewswire.com/news-releases/tarsier-pharma-raises-capital-to-execute-phase-3-clinical-trial-301361616.html
https://www.prnewswire.com/il/news-releases/tarsier-pharma-completes-successful-pre-ind-meeting-with-the-fda-for-its-trs02-program-of-back-of-the-eye-blinding-indications-301276620.html
https://www.prnewswire.com/news-releases/tarsier-pharma-completes-successful-pre-ind-meeting-with-the-fda-for-its-trs02-program-of-back-of-the-eye-blinding-indications-301276620.html
Market Place
Share 
